Open AccessEvaluation of the impact of gonadotropin-releasing hormone agonist as an adjuvant in luteal-phase support on IVF outcome
Author(s) -
Dattaprasad B. Inamdar,
Abha Majumdar
Publication year - 2012
Publication title -
journal of human reproductive sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.484
H-Index - 31
eISSN - 0974-1208
pISSN - 1998-4766
DOI - 10.4103/0974-1208.106341
Subject(s) - medicine , pregnancy , luteal phase , agonist , pregnancy rate , randomization , embryo transfer , gonadotropin releasing hormone agonist , triptorelin , gynecology , placebo , randomized controlled trial , gestation , obstetrics , hormone , gonadotropin releasing hormone , buserelin , luteinizing hormone , biology , receptor , genetics , alternative medicine , pathology
To evaluate whether three daily doses of GnRH agonist (Inj. Lupride 1 mg SC) administered 6 days after oocyte retrieval increases ongoing pregnancy rates following embryo transfer (ET) in cycles stimulated with the long GnRH agonist protocol.